Browse Studies — Arctuva

Observational

Impact of Barostimulation in Cardiac Hemodynamics and Clinical Outcomes Through Use of the Barostim™ CVRx Device

This study evaluates the effects of the implantation and adjustment of the CVRx Barostim device in adult patients with heart failure with reduced ejection frac…

HFrEF - Heart Failure With Reduced Ejection Fraction

Estimated

~$10 – $6,250

Columbia UniversityNCT07335510

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Using COR ECG Wearable Monitor

This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as…

Ventricular Ejection FractionLVFLV Dysfunction+12 more

Estimated

~$10 – $1,050

Peerbridge Health, IncNCT06699056

Phase 1

A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction

It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac c…

Congestive Heart FailureHeart Failure, SystolicHeart Failure+1 more

Estimated

~$10 – $8,750

Sardocor Corp.NCT04703842

Phase 2

A Phase 2a, Open-Label Study to Assess the Safety, Tolerability, and Efficacy of JK07 in Participants With Heart Failure and Group 2 Combined Post-Capillary and Pre-Capillary Pulmonary Hypertension (RENEU-PH)

This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnos…

HFrEF - Heart Failure With Reduced Ejection FractionHFpEF - Heart Failure With Preserved Ejection FractionGroup 2 Pulmonary Hypertension

Estimated

~$10 – $8,750

Salubris Biotherapeutics IncNCT07221513